What is the fair value of Adc Therapeutics SA (NYSE-ADCT) stock?

The current fair value estimate for Adc Therapeutics SA (NYSE-ADCT) is $1.46. This implies an estimated upside of 15.6% versus the current market price.

Is Adc Therapeutics SA (NYSE-ADCT) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 15.6% versus the current market price.

What is the analyst price target for NYSE-ADCT stock?

The available analyst price target for Adc Therapeutics SA (NYSE-ADCT) is $5. The analyst target implies estimated upside of 296.8%.

How is the financial health of Adc Therapeutics SA?

The current financial health read for Adc Therapeutics SA (NYSE-ADCT) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Adc Therapeutics SA's next earnings date?

The next earnings date currently listed for Adc Therapeutics SA (NYSE-ADCT) is August 11, 2026.

Does Adc Therapeutics SA (NYSE-ADCT) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for Adc Therapeutics SA (NYSE-ADCT)?

The current P/E ratio listed for Adc Therapeutics SA (NYSE-ADCT) is -1.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of Adc Therapeutics SA?

The current market capitalization listed for Adc Therapeutics SA is 160.3 M.

What is the enterprise value of Adc Therapeutics SA?

The current enterprise value listed for Adc Therapeutics SA is 366.1 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Adc Therapeutics SA?

The ticker symbol for Adc Therapeutics SA is NYSE-ADCT, and the stock is listed on NYSE.

Where is Adc Therapeutics SA (NYSE-ADCT) listed?

Adc Therapeutics SA (NYSE-ADCT) is listed on NYSE.

What is the debt-to-total-capital ratio for Adc Therapeutics SA?

The current debt-to-total-capital ratio listed for Adc Therapeutics SA is 73.1%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Adc Therapeutics SA?

The free float listed for Adc Therapeutics SA is 78.9%. Free float helps investors understand how much of the share base is available for public trading.

Adc Therapeutics SA (ADCT) Fair Value & Stock Analysis

Adc Therapeutics SA (ADCT)

ADC Therapeutics SA is a biotechnology company focused on antibody-drug conjugate technology. The company is based in Epalinges, Switzerland, and also operates in the United States. Its lead product is ZYNLONTA, a CD19-directed ADC approved for use in relapsed or refractory diffuse large B-cell lymphoma after at least two prior lines of systemic therapy, with regulatory clearances in the United States, European Union, and China. ADC Therapeutics is also working to broaden ZYNLONTA’s use into additional lymphoma settings through ongoing clinical studies, including confirmatory and early-stage trials. Its pipeline includes ADCT-602, a CD22-targeted candidate being studied in refractory B-cell acute lymphoblastic leukemia, as well as several preclinical ADC programs aimed at other targets. The company was incorporated in 2011 and is listed as common stock on the NYSE.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NYSE-ADCT	$1.46	15.6% Upside	Fair	$5	296.8% Upside	Bargain	Fair	—	—	—	0.0%	August 11, 2026	-1.2x	-0.7x	2.0x	160.3 M	366.1 M	73.1%	78.9%	-13.5	—	83.6%

Send a message